<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

PANC-1

Description

PANC-1 (Pancreatic Cancer CDX Model) 

The PANC-1 pancreatic cancer cell line was derived from a ductal adenocarcinoma of the pancreas. It carries a KRAS mutation, reflecting one of the most common drivers in pancreatic ductal adenocarcinoma (PDAC). PANC-1 exhibits aggressive biology and reproducible xenograft growth. Its stability makes it a widely used PDAC research model. 

Key Features: 

  • Derived from pancreatic ductal adenocarcinoma. 
  • KRAS-mutant pancreatic model. 
  • Aggressive growth phenotype. 
  • Tumorigenic in xenografts. 

Applications: 
PANC-1 supports therapeutic development in pancreatic cancer. Researchers use it to evaluate chemotherapies, targeted therapies, and drug delivery approaches. It is also applied in biomarker and resistance studies. Its reproducibility ensures value across translational PDAC research.

Details
Tumor Type
Pancreatic
Tumor Subtype
Pancreatic Ductal Adenocarcinoma
Organism
Human
Mouse Sex
Female
Mouse Strain
Athymic Nude
Mutated Genes
KRAS
Mutation: p.G12D
Effect: Missense Variant
Impact: Association & Pathogenic & Pathogenic / Likely Pathogenic & Likely Pathogenic & Not Provided
TP53
Mutation: p.R273H
Effect: Missense Variant
Impact: Pathogenic / Likely Pathogenic & Pathogenic & Likely Pathogenic
Lumin Data
Proteomics
Expression Data
Growth Curve
View on Lumin